Autologous tumor lysate-pulsed dendritic cell vaccination therapy after resection of stage IIA (T2N0, T3N0) esophageal cancer: An analysis of immunological responses.
/in Dendritic Cells, Esophageal Carcinoma, International Publications /von 2018-01-26 / J Clin Oncol 36, 2018 (suppl 5S; abstr 96)A prospective, randomized, blinded, placebo-controlled, phase IIb trial of an autologous tumor lysate + yeast cell wall particles (YCWP) + dendritic cells (DC) vaccine vs unloaded YCWP + DC and embedded phase I/IIa trial with tumor lysate particle only (TLPO) vaccine in stage III and stage IV (resected) melanoma to prevent recurrence.
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2018-01-25 / J Clin Oncol 36, 2018 (suppl 5S; abstr TPS201)A phase-1/2 study of adenovirus-p53 transduced dendritic cell vaccine in combination with indoximod in metastatic solid tumors and invasive breast cancer
/in Breast Cancer, Dendritic Cells, International Publications /von 2018-01-10 / Oncotarget 2018 Feb;9(11):10110-10117EpCAM peptide-primed dendritic cell vaccination confers significant anti-tumor immunity in hepatocellular carcinoma cells
/in Dendritic Cells, Hepatocellular Carcinoma, International Publications /von 2018-01-03 / PLoS ONE 2018;13(1):e0190638Phase I clinical trial of a novel autologous modified-DC vaccine in patients with resected NSCLC
/in Dendritic Cells, International Publications, NSCLC /von 2017-12-21 / BMC Cancer 2017 12;17(1):884Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human
/in Dendritic Cells, International Publications, Malignant Pleural Mesothelioma /von 2017-12-12 / Clin. Cancer Res. 2018 Feb;24(4):766-776Advances in immunotherapeutic research for glioma therapy
/in Dendritic Cells, Glioblastoma, International Publications /von 2017-12-05 / J. Neurol. 2018 Apr;265(4):741-756An update on the relevance of vaccine research for the treatment of metastatic melanoma
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2017-11-23 / Melanoma Manag 2017 Dec;4(4):203-215A phase I vaccination study with dendritic cells loaded with NY-ESO-1 and α-galactosylceramide: induction of polyfunctional T cells in high-risk melanoma patients
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2017-11-01 / Cancer Immunol. Immunother. 2018 02;67(2):285-298
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de